Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) aren't the only mRNA coronavirus vaccine makers in town. In fact, another company has been gaining ground -- and reported pivotal trial results this week. I'm talking about German biotech CureVac (NASDAQ: CVAC) .
Even though CureVac is a latecomer, investors still have closely followed the company's vaccine story because it could be a big supplier in Europe. The European Commission already has signed an advance purchase agreement for as many as 405 million doses from the company.
However, 12 words from the company's CEO this week may mean billions of dollars for Moderna and Pfizer... and a lot less for CureVac.
For further details see:
12 Words From CureVac's CEO That Could Mean Billions for Moderna and Pfizer